Xiaolei Li

Dr. Xiaolei Li

Department of Orthodontics, University of Pennsylvania, Philadelphia, Mississippi, USA
orcid
Department of Orthodontics, School of Dental Medicine, Unive...

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in ACS Nano
Verified
Journal Article
Closed access
MLMeng Liu
Meng Liu
LHLing Huang
Ling Huang
XXXingyi Xu
Xingyi Xu
XWXiaoming Wei
Xiaoming Wei
XYXianfeng Yang
Xianfeng Yang
ZYZhongmin Yang
Zhongmin Yang

7 February 2024 in Advanced Materials
Verified
Journal Article
Closed access
Xiaolei LiXiaolei Li
Xiaolei Li
HLHan Lin
Han Lin
YYYilin Yu
Yilin Yu
YLYukun Lu
Yukun Lu
BHBin He
Bin He
WLWeichang Li
Weichang Li

1 December 2021 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
YYYilin Yu
Yilin Yu
Xiaolei LiXiaolei Li
Xiaolei Li
JLJiarun Li
Jiarun Li
DLDongying Li
Dongying Li
QWQinmei Wang
Qinmei Wang
WTWei Teng
Wei Teng

1 August 2018 in Materials & Design
Verified
Journal Article
Closed access
Xiaolei LiXiaolei Li
Xiaolei Li
WWWei Wang
Wei Wang
QLQianli Li
Qianli Li
HLHan Lin
Han Lin
YXYue Xu
Yue Xu
LZLin Zhuang
Lin Zhuang

27 December 2021 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
DMDongxu Ma
Dongxu Ma
BCBaiqi Chen
Baiqi Chen
YLYuanfang Li
Yuanfang Li
XPXueyuan Pang
Xueyuan Pang
QFQuanying Fu
Quanying Fu
JZJianhua Zhou
Jianhua Zhou

15 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SNSusheel Kumar Nethi
Susheel Kumar Nethi
Xiaolei LiXiaolei Li
Xiaolei Li
SBShubhmita Bhatnagar
Shubhmita Bhatnagar
SPSwayam Prabha
Swayam Prabha
Mesenchymal stem cells (MSCs) have been studied for their potential in facilitating tumor-targeted delivery of chemotherapeutics due to their tumor-homing characteristics. We hypothesized that targeting effectiveness of MSCs can be further enhanced by incorporating tumor-targeting ligands on MSC surfaces that will allow for enhanced arrest and binding within the tumor tissue. We utilized a unique strategy of modifying MSCs with synthetic antigen receptors (SARs), targeting specific antigens overexpressed on cancer cells. MSCs were surface-functionalized by first incorporating recombinant protein G (PG) on the surface, followed by binding of the targeting antibody to the PG handle. We functionalized MSCs with antibodies targeting a tyrosine kinase transmembrane receptor protein, epidermal growth factor receptor (EGFR), overexpressed in non-small-cell lung cancer (NSCLC). The efficacy of MSCs functionalized with anti-EGFR antibodies (cetuximab and D8) was determined in murine models of NSCLC. Cetuximab-functionalized MSCs demonstrated improved binding to EGFR protein and to EGFR overexpressing A549 lung adenocarcinoma cells. Further, cetuximab-functionalized MSCs loaded with paclitaxel nanoparticles were efficient in slowing orthotopic A549 tumor growth and improving the overall survival relative to that of other controls. Biodistribution studies revealed a six-fold higher retention of EGFR-targeted MSCs than non-targeted MSCs. Based on these results, we conclude that targeting ligand functionalization could be used to enhance the concentration of therapeutic MSC constructs at the tumor tissue and to achieve improved antitumor response.